The combination of FA-HP-β-CyD and ABL tyrosine kinase inhibitors (imatinib and ponatinib) had a synergistic inhibitory effect on CML cells. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.